Circulating microRNAs in plasma as early detection markers for breast cancer.
about
Extracellular MicroRNA in liquid biopsy: applicability in cancer diagnosis and preventionDiagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: systematic review and qualitative meta-analysismiRNAs as potential biomarkers in early breast cancer detection following mammographyTumor-Associated CSF MicroRNAs for the Prediction and Evaluation of CNS MalignanciesMicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potentialCirculating microRNAs: potential biomarkers for common malignanciesIndividual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumorsAnalysis of circulating microRNAs in adrenocortical tumorsIdentification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast CancerComprehensive characterization of serum microRNA profile in response to the emerging avian influenza A (H7N9) virus infection in humans.MicroRNAs in pathogenesis of breast cancer: Implications in diagnosis and treatment.Usefulness of miRNA profiles for predicting pathological responses to neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer.miR-376c promotes carcinogenesis and serves as a plasma marker for gastric carcinomaMicroRNA Expression Varies according to Glucose Tolerance, Measurement Platform, and Biological Source.Different miRNA expression profiles between human breast cancer tumors and serumCancer-derived Circulating MicroRNAs Promote Tumor Angiogenesis by Entering Dendritic Cells to Degrade Highly Complementary MicroRNAs.Abundant circulating microRNAs in breast cancer patients fluctuate considerably during neoadjuvant chemotherapy.Alterations in circulating miRNA levels following early-stage estrogen receptor-positive breast cancer resection in post-menopausal women.miRNA as potential biomarkers of breast cancer in the Lebanese population and in young women: a pilot study.Circulating miR-148b and miR-133a as biomarkers for breast cancer detection.Cell-free nucleic acids as non-invasive biomarkers of gynecological cancers, ovarian, endometrial and obstetric disorders and fetal aneuploidy.Clinical implications of microRNAs in cancer.Impact of the genetic background on the composition of the chicken plasma MiRNome in response to a stressDeep Sequencing of Serum Small RNAs Identifies Patterns of 5' tRNA Half and YRNA Fragment Expression Associated with Breast Cancer.Circulating miRNA biomarkers for Alzheimer's diseaseMiR-148b suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting WNT1/β-catenin pathway.Plasma microRNA panel for minimally invasive detection of breast cancerInfluence of plasma processing on recovery and analysis of circulating nucleic acids.Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer.Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management.Critical analysis of the potential for microRNA biomarkers in breast cancer management.MicroRNAs as potential biomarkers in cancer: opportunities and challengesGHSR DNA hypermethylation is a common epigenetic alteration of high diagnostic value in a broad spectrum of cancersDiagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR.Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer.RETRACTED: Decrease expression and clinicopathological significance of miR-148a with poor survival in hepatocellular carcinoma tissuesGene and miRNA expression signature of Lewis lung carcinoma LLC1 cells in extracellular matrix enriched microenvironment.Plasma microRNA biomarkers for detection of mild cognitive impairment.Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study.Personalized medicine in screening for malignant disease: a review of methods and applications.
P2860
Q26742027-0DA70316-C7CE-42DA-A092-810BB61A9F48Q26748767-CB588A1A-A7FA-440E-94E3-5888D2126586Q26773094-50CE8102-19EE-4AE7-8581-82A9C602B34BQ26774431-FEB1DF77-116D-480C-B9CA-829C866EF995Q28081081-211A5A74-1AF7-4743-B1FD-0FCFD5893908Q28081347-CA5C57D4-2638-443F-A367-0D36C2A200B3Q28302352-0F1AEE32-EDC3-48AD-898E-E7A1821877ABQ28303947-6B62C808-BAAB-465C-BED8-2134B6B99A76Q28552581-1B3515D9-DA4B-4E24-B500-FC8600542F6DQ33584750-F8EC521F-AA38-43E2-83F9-AFA501186112Q33585094-E74772D4-4475-4F38-B94A-6733CFFF22ECQ33599465-3E19DF58-95CD-4FC9-83F1-964712A40ECEQ33653161-43267AD8-8553-4510-964F-50965A831392Q33654397-D25CEDAC-96D0-4CDA-AF3E-EC9A14B776D9Q33663601-3EB136D1-18B4-4ED7-86E6-87D8660DEB53Q33703057-2A605325-F7DA-4608-867E-A3D29B2EEB26Q33844289-748B8A0F-74A5-4D37-947B-08CB2206FB6DQ33864278-A3FFF96A-C0A3-4376-9C2B-290709BFDC9BQ34215056-4ACFA4B5-C1DB-472E-8744-31B46C0740F1Q34221705-A0D2052C-A6D9-4184-BFC3-9203FE0FD0DDQ34426839-B660DE8C-2F4F-42DD-A26C-C099BB542267Q34570698-E1B06B02-B470-4872-8203-41D462730614Q34634715-103F0E5D-0F6E-4D1A-B051-02AF265E8EBFQ34662408-C6CFAB2A-76A0-43E4-A5BD-3A7F54EECC7AQ34904013-CC4F5746-4CA0-4CE5-A5A5-F7A81CF58980Q35025308-2381E080-F30A-4906-A635-7D3502A7CEE8Q35032320-0AB4A982-AD25-4379-B92A-5A0674BE06F4Q35035846-47B9A7E0-7ADE-4B51-8E16-B149DBF6CFDBQ35093548-5BF22972-3D6F-4DCB-8F4E-7BF2BD5B956DQ35094742-05E67890-871D-49AB-BA19-26B64D26C6DDQ35137273-D250F373-2C4D-47BC-87C0-DD60B72F6900Q35271157-4C846784-3D8B-4279-95EB-5274E167C6BFQ35552037-17F22186-EFAD-44A1-AC32-69092AB38B12Q35789307-EA2EEB8B-654D-4474-AAD3-0B8B572587EFQ35791145-9031357A-B51B-4BC3-B398-CDE60D8E7394Q35926654-7310DA01-4F50-4ABF-AC61-D1AD97F8929BQ36160786-708F8A7B-7C5B-42C6-AFB2-E20470F84CE5Q36380583-8416B412-5173-4E7F-80DD-DD6708A7BB2CQ36487046-AAD564F6-1C8B-4A53-98B7-8C2D794D2EB4Q36641610-9BF89BB7-C861-4DB7-AFCF-EA29808E2B9D
P2860
Circulating microRNAs in plasma as early detection markers for breast cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Circulating microRNAs in plasma as early detection markers for breast cancer.
@en
Circulating microRNAs in plasma as early detection markers for breast cancer.
@nl
type
label
Circulating microRNAs in plasma as early detection markers for breast cancer.
@en
Circulating microRNAs in plasma as early detection markers for breast cancer.
@nl
prefLabel
Circulating microRNAs in plasma as early detection markers for breast cancer.
@en
Circulating microRNAs in plasma as early detection markers for breast cancer.
@nl
P2093
P2860
P50
P356
P1476
Circulating microRNAs in plasma as early detection markers for breast cancer.
@en
P2093
Andrey Turchinovich
Axel Benner
Christof Sohn
Dharanija Madhavan
Dorit Arlt
Hans Junkermann
Katarina Cuk
Manuela Zucknick
Michelle Rath
P2860
P304
P356
10.1002/IJC.27799
P577
2012-09-14T00:00:00Z